Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Given the severity of the SARS-CoV-2 pandemic, a major challenge is to rapidly repurpose existing approved drugs for clinical interventions. While a number of data-driven and experimental approaches have been suggested in the context of drug repurposing, a platform that systematically integrates available transcriptomic, proteomic and structural data is missing. More importantly, given that SARS-CoV-2 pathogenicity is highly age-dependent, it is critical to integrate aging signatures into drug discovery platforms. We here take advantage of large-scale transcriptional drug screens combined with RNA-seq data of the lung epithelium with SARS-CoV-2 infection as well as the aging lung. To identify robust druggable protein targets, we propose a principled causal framework that makes use of multiple data modalities. Our analysis highlights the importance of serine/threonine and tyrosine kinases as potential targets that intersect the SARS-CoV-2 and aging pathways. By integrating transcriptomic, proteomic and structural data that is available for many diseases, our drug discovery platform is broadly applicable. Rigorous in vitro experiments as well as clinical trials are needed to validate the identified candidate drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
UMAP: Uniform Manifold Approximation and Projection
McInnes, L., Healy, J., Saul, N., & Großberger, L. (2018) · Journal of Open Source Software · doi:10.21105/joss.00861 · Cited by 9,826
Abadie, A., Diamond, A., & Hainmueller, J. (2010) · Journal of the American Statistical Association · doi:10.1198/jasa.2009.ap08746 · Cited by 5,513
Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Causation, Prediction, and Search
Spirtes, P., Glymour, C., & Scheines, R. (2001) · doi:10.7551/mitpress/1754.001.0001 · Cited by 4,521
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171 · cited 3×
“Given the stark increase in case fatality rates of COVID-19 after age 70 [17, 18], we performed a differential expression analysis comparing the youngest group (20-29 years old) and oldest group (70-79 years old), thereby identifying 1923 genes differentially regulated in aging (Fig.”
BackgroundMethodInfluentialA Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles
Subramanian, A., Narayan, R., Corsello, S. M., Peck, D. D., Natoli, T. E., Lu, X., Gould, J., Davis, J. F., Tubelli, A. A., Asiedu, J. K., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.049 · Cited by 3,515
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Reyfman, P. A., Walter, J. M., Joshi, N., Anekalla, K. R., McQuattie-Pimentel, A. C., Chiu, S., Fernandez, R., Akbarpour, M., Chen, C.-I., Ren, Z., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2410oc · Cited by 1,203
Cited by
Lv, H., Shi, L., Berkenpas, J. W., Dao, F.-Y., Zulfiqar, H., Ding, H., Zhang, Y., Yang, L., & Cao, R. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbab320 · Cited by 107
“[ 37] proposed a computational method for drug repurposing.”
Cell deaths: Involvement in the pathogenesis and intervention therapy of COVID-19
Li, X., Zhang, Z., Wang, Z., Gutiérrez-Castrellón, P., & Shi, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01043-6 · Cited by 67
“Both the RNA-sequencing data and proteome-wide data analysis revealed that RIPK1 is a potential drug target for COVID-19 patients.(98,99) The FDA-approved drug primidone has the property to reduce RIPK1mediated necroptosis in vitro and TNFα-induced inflammation in vivo,(100) which may be beneficial to patients with CO…”
Li, V. O., Han, Y., Kaistha, T., Zhang, Q., Downey, J., Gozes, I., & Lam, J. C. (2024) · doi:10.1101/2024.07.06.24309990 · Cited by 8
Berrevoets, J., Kacprzyk, K., Qian, Z., & van der Schaar, M. (2023) · arXiv · doi:10.48550/arxiv.2303.02186 · Cited by 8
“…methods using a general multi-domain causal structure [23–25] Treatment effects Learn models that respect identification assumptions [26–39] Drug repurposing Relate multi-modal data using causal structure [40–44] Recommendation Infer causal effect of recommendation [45–49] Table 1: Real-world impact.”
Method
Metadata
- Authors
- Belyaeva, A., Cammarata, L., Radhakrishnan, A., Squires, C., Yang, K. D., Shivashankar, G. V., & Uhler, C.
- Venue
- Nature Communications
- Published
- 2021-02-15
- Volume
- 12
- Issue
- 1
- Pages
- 1024-1024
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3032892710
- Cited by
- 63
- References
- 16
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing. https://app.cochat.ai/papers/10.1038/s41467-021-21056-z
- The paper
- Belyaeva, A., Cammarata, L., Radhakrishnan, A., Squires, C., Yang, K. D., Shivashankar, G. V., & Uhler, C. (2021). Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing. Nature Communications. https://doi.org/10.1038/s41467-021-21056-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.